Provenance Wealth Advisors LLC Buys 2,008 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Provenance Wealth Advisors LLC boosted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 20,080.0% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,018 shares of the pharmaceutical company’s stock after purchasing an additional 2,008 shares during the quarter. Provenance Wealth Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $1,055,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Associated Banc Corp purchased a new stake in Vertex Pharmaceuticals during the third quarter valued at approximately $3,117,000. Putney Financial Group LLC boosted its stake in Vertex Pharmaceuticals by 6.1% in the third quarter. Putney Financial Group LLC now owns 468 shares of the pharmaceutical company’s stock valued at $245,000 after acquiring an additional 27 shares in the last quarter. Factory Mutual Insurance Co. purchased a new position in Vertex Pharmaceuticals in the third quarter worth $2,398,000. Aware Super Pty Ltd as trustee of Aware Super grew its holdings in Vertex Pharmaceuticals by 121.9% in the third quarter. Aware Super Pty Ltd as trustee of Aware Super now owns 20,055 shares of the pharmaceutical company’s stock worth $10,485,000 after purchasing an additional 11,017 shares during the last quarter. Finally, Trek Financial LLC increased its position in shares of Vertex Pharmaceuticals by 6.2% during the third quarter. Trek Financial LLC now owns 686 shares of the pharmaceutical company’s stock worth $359,000 after purchasing an additional 40 shares in the last quarter. 90.96% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

VRTX has been the subject of several analyst reports. JPMorgan Chase & Co. increased their price objective on Vertex Pharmaceuticals from $560.00 to $570.00 and gave the company an “overweight” rating in a report on Tuesday. Morgan Stanley lowered their price objective on Vertex Pharmaceuticals from $665.00 to $660.00 and set an “overweight” rating for the company in a research report on Tuesday. Rothschild & Co Redburn boosted their target price on Vertex Pharmaceuticals from $570.00 to $580.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Stifel Nicolaus upped their target price on Vertex Pharmaceuticals from $500.00 to $563.00 and gave the company a “hold” rating in a research report on Tuesday. Finally, Weiss Ratings upgraded Vertex Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, October 16th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $596.44.

Vertex Pharmaceuticals Trading Up 3.4%

Shares of Vertex Pharmaceuticals stock opened at $549.04 on Thursday. The company has a current ratio of 2.34, a quick ratio of 2.74 and a debt-to-equity ratio of 0.17. Vertex Pharmaceuticals Incorporated has a 12-month low of $406.67 and a 12-month high of $568.67. The firm has a market capitalization of $139.35 billion, a price-to-earnings ratio of 35.33, a PEG ratio of 2.56 and a beta of 0.28. The firm’s 50 day simple moving average is $522.90 and its two-hundred day simple moving average is $480.92.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.06). Vertex Pharmaceuticals had a return on equity of 21.98% and a net margin of 30.70%. The company had revenue of $3.44 billion during the quarter, compared to analysts’ expectations of $3.42 billion. During the same period in the prior year, the business posted $4.80 EPS. The company’s quarterly revenue was up 11.8% on a year-over-year basis. Analysts predict that Vertex Pharmaceuticals Incorporated will post 16.64 EPS for the current year.

Vertex Pharmaceuticals News Summary

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex reported third-quarter revenue of $3.44 billion, up 12% year over year and ahead of estimates, with cystic fibrosis medicines and newer products including CASGEVY and JOURNAVX contributing. The company raised its 2026 revenue outlook, while management highlighted the potential for povetacicept, which faces an FDA decision for IgA nephropathy on November 30. Vertex Q3 2026 earnings call highlights
• Positive Sentiment: Analyst actions have generally been supportive: Barclays raised its price target to $626 and kept an overweight rating, while H.C. Wainwright reiterated Buy and TD Cowen also rated the shares Buy. These endorsements may bolster confidence in Vertex’s growth prospects.
• Neutral Sentiment: Investors are also focused on Vertex’s efforts to expand beyond cystic fibrosis into kidney and rare endocrine diseases—potential future growth drivers, but ones that will take time to establish. Vertex: 3 key takeaways for long-term investors
• Negative Sentiment: Quarterly earnings per share came in below analyst expectations, and acquisition costs weighed on profit. Reports also pointed to lighter-than-hoped-for sales of the pain drug JOURNAVX, contributing to a selloff after the earnings release. Vertex slumps on light pain drug sales

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.